MPM BioImpact’s Arcellx ACLX Stock Holding History

MPM BioImpact’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37	Closed	-$2.44K	–	41
2025 Q2	$2.44K	Buy	+37	New	+$2.3K	﹤0.01%	44

Other funds holding ACLX

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

MPM BioImpact's ACLX Position: Q3 2025 in Review

MPM BioImpact sold out of Arcellx (ACLX) in Q3 2025, closing a stake of 37 shares — an estimated $2.44K sold.

MPM BioImpact first reported a position in ACLX in Q2 2025 and held it in 1 quarter. The position peaked at $2.44K in Q2 2025. 209 funds tracked by Wall St. Rank hold ACLX as of Q3 2025.

MPM BioImpact reported no remaining Arcellx position as of Q3 2025 after selling out during the quarter.
MPM BioImpact sold 37 Arcellx shares in Q3 2025, an estimated $2.44K.
MPM BioImpact first reported a position in Arcellx in Q2 2025 and held it in 1 quarter.
MPM BioImpact's Arcellx position peaked at $2.44K in Q2 2025.
209 funds tracked by Wall St. Rank held Arcellx as of Q3 2025.

Based on MPM BioImpact's 13F filing for Q3 2025, filed 14 Nov 2025.